Skip to main content

Nuclea Announces $3.4M in Additional Financing

NEW YORK (GenomeWeb News) – Nuclea Biotechnologies said today it has closed on an additional $3.4 million in funding and committed financing, which it will use to continue development of its technology.

The financing includes $1.4 million in additional cash and $2 million in future commitments running through March 31, and finalizes Nuclea's Series B financing round. In October the company announced it raised $6.4 million in the round, and today's announcement brings the total Series B amount to $9.8 million.

Based in Pittsfield, Mass., Nuclea develops diagnostic assays based on fatty acid synthase, a biomarker for tumors. It said the funding will support its regulatory efforts in developing the technology, including clinical trials, facility upgrades, new hires, and general operations.

Nuclea CFO Robert Pierce said in a statement that the new round of financing is a "vital step" as it prepares to commercialize its tests. Last month the company said that it submitted premarket IDE filings with the US Food and Drug Administration for its breast cancer and prostate cancer assays.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.